Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, focusing on brain-machine interface technologies and companies like Microinvasive Brain Science, Xiangyu Medical, and Aipeng Medical [1]. Core Insights - The report highlights significant advancements in the brain-machine interface sector, particularly the approval of the first product, which marks a pivotal moment for the industry. This approval is expected to facilitate further commercialization and development within the sector [18][24]. - The report ranks sub-industries in the following order of attractiveness: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies. It emphasizes high elasticity in innovative drugs, especially in small nucleic acid therapies, and high dividend yields in traditional Chinese medicine and pharmacies [3][11]. Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a slight decline of -0.22% this week and -0.13% year-to-date, underperforming the CSI 300 index by -0.41% and -0.97% respectively. The Hang Seng Biotechnology Index has also decreased by -4.00% this week [11]. - Notable stock performances include Yingke Medical (+35.18%), Zhonghong Medical (+25.26%), and *ST Jingfeng (+15.64%) for gains, while Yifang Biological (-11.59%) and Huakang Clean (-10.79%) faced significant losses [11]. R&D Progress and Company Dynamics - The report details the approval of several innovative drugs, including HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enoglutide, which has received approval in China [2][3]. - Companies to watch include: - From the PD1 PLUS perspective: Sanofi Biopharma, Kangfang Biopharma, and others - From the ADC perspective: Ying'en Biopharma and others - From the small nucleic acid perspective: Frontier Biopharma and others - From the CXO and upstream research services perspective: WuXi AppTec and others [3][14]. Brain-Machine Interface Developments - The report emphasizes the approval of the NEO brain-machine interface by the National Medical Products Administration, which is the first of its kind globally. This product is designed for patients with cervical spinal cord injuries and offers a minimally invasive solution with high signal quality and low tissue damage [18][20]. - The approval is seen as a breakthrough that sets a standard for future products in the brain-machine interface space, supported by government policies and funding initiatives aimed at fostering industry growth [24][25].

Group 1: Company Overview - Aipeng Medical focuses on medical devices, particularly in pain management and nasal airway management, while also exploring brain-computer interface innovations [4] - The company has established a joint laboratory with Fudan University to integrate research and clinical applications for ADHD treatment [6] Group 2: Product Development and Market Position - The company has developed a non-invasive ADHD behavior management system that connects data between clinical and home settings, currently in the early stages of commercialization [5] - Aipeng Medical's anesthesia depth monitoring device has a low market penetration in China, with less than 20% of surgical units equipped with such devices [7] - The company's pain pump holds a market share of approximately 23%, leading the market, with expectations to increase as it transitions to insurance coverage [8] Group 3: Future Trends and Market Potential - The brain-computer interface market in China is projected to reach approximately 3.8 billion yuan by the end of 2025, with an annual growth rate of nearly 20% [11] - The company prioritizes non-invasive brain-computer interface commercialization while considering strategic expansions into high-barrier invasive technologies [11]

证券代码：300753 证券简称：爱朋医疗 公告编号：2026-004 股东北京章泓私募基金管理有限公司-章泓精选1号私募证券投资基金保证向本 公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）于 2025 年 11 月 12 日在巨潮 资讯网（http://www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股份的预披露公 告》（公告编号：2025-052），持有本公司 7,058,000 股（占公司总股本的 5.60%）的持 股 5%以上股东北京章泓私募基金管理有限公司-章泓精选 1 号私募证券投资基金（以下 简称"章泓基金"），计划自上述公告披露之日起十五个交易日后的三个月内以集中竞 价交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总股本的 1%）；以大 宗交易方式减持所持有的本公司股份不超过 1,260,480 股（占公司总股本的 1%）。 2026 年 1 月 8 日，公司披露了《关于持股 5%以上股东减持至 5%以下暨权益变 ...

Core Insights - The pharmaceutical and biotechnology sector is experiencing increased institutional interest, particularly in brain-computer interface (BCI) stocks, driven by advancements in technology and commercialization efforts [1][2][3] Group 1: Brain-Computer Interface (BCI) Stocks - BCI stocks such as Xiangyu Medical, Aipeng Medical, and Meihao Medical have attracted significant institutional attention, with Xiangyu Medical receiving 208 institutional inquiries, Aipeng Medical 177, and Meihao Medical 125 [1] - Xiangyu Medical plans to upgrade 27 core products by mid-2026 and aims to launch nearly 100 BCI products by the end of 2026, focusing on multi-modal and multi-paradigm applications [2] - Aipeng Medical emphasizes the rapid growth of the BCI industry, particularly in non-invasive applications, and is prioritizing commercialization strategies based on existing technologies and channels [2] - Meihao Medical aims to be a key supplier in the BCI field, enhancing its competitive edge in invasive BCI implants through increased R&D investment and collaboration with clients [2][3] Group 2: Globalization of Pharmaceutical Companies - Domestic pharmaceutical companies are focusing on global strategies, with an emphasis on the commercialization of innovative drugs abroad [4][5] - MediXis has established a 2,000 square meter R&D office in Boston to support its global strategy, with overseas revenue expected to account for approximately 47% of total income by 2025 [4] - Huayuan Pharmaceutical has set up multiple business and R&D centers globally, with overseas revenue reaching 43% of total income in the first half of 2025 [4][5] - The "innovation + internationalization" strategy remains a core focus for the sector, with increasing participation of Chinese companies in global pharmaceutical collaborations [6]

Group 1 - The core focus of Aipeng Medical (300753) in recent days has been on the progress of its brain-computer interface business and institutional research interest [1] - The anesthesia puncture robot project is still in the design and development stage, with no significant breakthroughs reported [1] - Brain-computer interface technology has become a key focus for institutional research, highlighting advancements in EEG technology and the commercialization of cutting-edge brain state research, driven by policy support and technological breakthroughs [1] Group 2 - The stock price of Aipeng Medical has shown volatility, influenced by sentiment in the brain-computer interface sector [2] - On February 11, 2026, the stock price fell by 1.11% with a trading volume of 118 million yuan and a net outflow of main funds [2] - The stock had previously risen by 4.13% on February 6, 2026, closing at 34.57 yuan, driven by inflows related to the brain-computer interface concept [2] - As of February 12, 2026, the stock price was 33.39 yuan, reflecting a 1.37% increase from the previous day, but a cumulative decline of 3.41% over the past five days, indicating short-term market divergence [2]

Group 1 - The core viewpoint of the article highlights the increasing investment and research activity in the brain-computer interface (BCI) industry in China, with a focus on key companies and patent trends [1][4][5] Group 2 - The research and development investment in the BCI industry by listed companies in China is steadily increasing from 2020 to 2024, indicating a strengthening of R&D efforts [1] - The number of patent applications in China's BCI industry showed a steady growth trend, peaking at 258 applications in 2021, followed by a decrease to 209 applications in 2024 [4] - Tianjin University is identified as the leading patent applicant in the BCI sector, with a total of 126 related patents, followed by South China University of Technology and Xi'an Jiaotong University with 80 and 78 patents respectively [5][7] - The most popular technology patents in the BCI industry are in the category of electrical digital data processing (G06F), with a total of 1,013 patents, followed by diagnostic and surgical technologies (A61B) with 712 patents, and specific computing models (G06N) with 313 patents [8]

Group 1: Innovation in Medical Technology - Innovation Medical (002173) has established itself in the medical service sector, focusing on brain-computer interface (BCI) technology for clinical applications, particularly in neuro-rehabilitation and cardiovascular treatment [1][20] - The company's BCI-4000 product is in Phase III clinical trials, utilizing invasive electrodes to collect brain signals for device control, aiding rehabilitation for high-level paraplegics [1][20] - With the implementation of insurance reimbursement policies for BCI, the clinical transition process is expected to accelerate, potentially leading to significant growth in the neuro-rehabilitation business [1][20] Group 2: Digital Entertainment and AI Integration - Talking Tom (300459) leverages its popular IPs in digital entertainment and is actively exploring the integration of AI with brain-computer interfaces to create immersive interactive experiences [2][21] - The core business includes IP operation, mobile app development, and digital content creation, focusing on leisure and children's education [2][21] - The company aims to develop brain-controlled games and immersive entertainment applications, enhancing user engagement and monetization capabilities [2][21] Group 3: Precision Components in Medical Devices - Meihua Medical (301363) specializes in manufacturing precision medical components, providing essential support to global medical device companies, and has recently entered the brain-computer interface supply chain [3][22] - The company produces components for cardiovascular and neuro-interventional devices, including precision structural parts for BCI equipment [3][22] - As demand for BCI devices increases, the company anticipates a steady growth in orders for precision components, enhancing collaboration with BCI firms [3][22] Group 4: AI and Brain-Computer Interface Algorithms - Yanshan Technology (002195) focuses on brain-like intelligence and AI, with a strong emphasis on developing neural signal decoding algorithms for brain-computer interfaces [4][23] - The company aims to optimize brain signal decoding efficiency through AI algorithms, enhancing the precision control capabilities of BCI devices [4][23] - As the demand for algorithm precision in BCI increases, the company expects growth in algorithm licensing and system integration services [4][23] Group 5: Network Solutions for Brain-Computer Interfaces - StarNet Ruijie (002396) is a leading provider of network equipment and solutions, exploring network support solutions for brain-computer interface applications [5][25] - The company offers high-speed data transmission and processing solutions for BCI devices, facilitating real-time brain signal transmission and cloud analysis [5][25] - With the rising demand for data transmission efficiency in BCI, the company anticipates continued growth in high-speed network equipment demand [5][25] Group 6: Pain Management and Neuroregulation - Aipeng Medical (300753) specializes in pain management and neuroregulation, exploring the application of brain-computer interfaces in postoperative pain relief and neuro-rehabilitation [6][26] - The company focuses on developing devices for pain management and neuroregulation, aiming to enhance treatment efficiency through brain-computer technology [6][26] - As the demand for neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [6][26] Group 7: Security and Identity Verification - Entropy Technology (301330) leverages biometric recognition and identity verification technologies, applying brain-computer interfaces in security and identity authentication [7][27] - The company provides solutions for financial, governmental, and transportation sectors, focusing on the development of BCI applications for secure interactions [7][27] - As the demand for precision and security in identity verification increases, the potential for BCI applications in security will gradually be realized [7][27] Group 8: Smart Control Components and IoT Solutions - Yingqu Technology (002925) specializes in smart control components and IoT solutions, providing essential support for brain-computer interface devices [8][28] - The company serves consumer electronics and smart home sectors, offering smart control components that facilitate intelligent interaction and data collection for BCI devices [8][28] - With the rising demand for intelligent BCI devices, the company expects a continuous increase in orders for smart control components [8][28] Group 9: Precious Metal Materials for BCI Electrodes - Guiyan Platinum (600459) focuses on the research and production of precious metal materials, providing critical materials for brain-computer interface electrodes [9][29] - The company supplies platinum-based alloy materials that enhance the biocompatibility and signal stability of BCI electrodes [9][29] - As the demand for mass production of BCI electrodes increases, the company anticipates a steady growth in orders for precious metal materials [9][29] Group 10: Automotive Applications of Brain-Computer Interfaces - Yachuang Electronics (301099) is exploring the application of brain-computer interfaces in smart driving, focusing on automotive-grade chips and power semiconductors [10][30] - The company aims to implement brain control technology for vehicle operation, opening new possibilities in automotive intelligence [10][30] - As the demand for human-machine interaction in smart driving increases, the potential for BCI applications in the automotive sector will gradually be realized [10][30] Group 11: Industrial Applications of Brain-Computer Interfaces - Zhongke Information (300678) focuses on intelligent monitoring and industrial detection, applying brain-computer interfaces in industrial settings [11][31] - The company aims to utilize brain signals for equipment status monitoring and fault prediction, enhancing industrial efficiency [11][31] - As the demand for monitoring precision in industrial automation increases, the application of BCI in industrial settings is expected to accelerate [11][31] Group 12: Third-Party Testing for BCI Compliance - Puni Testing (300887) is a leading third-party testing organization, providing compliance testing services for brain-computer interface devices [12][32] - The company offers testing for biocompatibility and electromagnetic compatibility, ensuring the safety and compliance of BCI products [12][32] - As the BCI industry matures, the demand for compliance testing services is expected to grow, supporting the healthy development of the industry [12][32] Group 13: Flexible Materials for BCI Devices - Pulit (002324) specializes in the research and production of polymer materials, providing essential flexible packaging materials for brain-computer interface devices [13][33] - The company enhances the durability and biocompatibility of BCI devices through its flexible packaging solutions [13][33] - As the demand for flexible materials in BCI devices increases, the company anticipates a steady growth in orders for packaging materials [13][33] Group 14: Intelligent Equipment and Robotics - Tianqi Co., Ltd. (002009) focuses on intelligent equipment manufacturing and industrial automation, exploring the application of brain-computer interfaces in industrial robotics [14][34] - The company aims to implement brain control technology for precise robotic operation, enhancing manufacturing efficiency [14][34] - As the demand for precision in industrial automation increases, the application of BCI in robotics is expected to accelerate [14][34] Group 15: Medical Rehabilitation and Training - Chengyitong (300430) specializes in pharmaceutical intelligent manufacturing and rehabilitation equipment, exploring the application of brain-computer interfaces in rehabilitation training [15][35] - The company focuses on optimizing rehabilitation plans through brain control technology, enhancing training efficiency [15][35] - As the demand for neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [15][35] Group 16: Military Communication and Navigation - Haige Communication (002465) is a core enterprise in military communication and navigation, providing specialized support for brain-computer interfaces [16][36] - The company offers military communication and data transmission solutions for BCI devices, enhancing interaction in specialized scenarios [16][36] - As the demand for BCI in military applications increases, the need for communication equipment is expected to grow [16][36] Group 17: Smart Terminals and Information Systems - Nanjing Panda (600775) leverages electronic manufacturing and communication technology, exploring the application of brain-computer interfaces in smart terminals [17][37] - The company aims to implement brain control technology for device operation, opening new possibilities in consumer electronics [17][37] - As the demand for interactive methods in smart terminals increases, the potential for BCI applications in consumer electronics will gradually be realized [17][37] Group 18: Biocompatible Coatings for BCI Devices - Taihe Technology (300801) specializes in fine chemicals and water treatment materials, providing essential biocompatible coating materials for brain-computer interface devices [18][38] - The company enhances the safety and durability of BCI devices through its biocompatible coatings [18][38] - As the demand for biocompatibility in BCI devices increases, the company anticipates a steady growth in orders for coating materials [18][38] Group 19: Cardiovascular and Neurointerventional Applications - Lepu Medical (300003) focuses on cardiovascular and neurointerventional fields, exploring the application of brain-computer interfaces in cardiac rehabilitation and neuroregulation [19][39] - The company aims to optimize treatment plans through brain control technology, enhancing rehabilitation efficiency [19][39] - As the demand for cardiovascular and neuro-rehabilitation grows, the application of BCI in medical settings is expected to accelerate [19][39] Group 20: Intelligent Nursing and Patient Monitoring - Yahua Electronics (301337) specializes in medical information systems and intelligent nursing devices, exploring the application of brain-computer interfaces in patient monitoring [20][40] - The company aims to utilize brain signals for real-time patient status monitoring, enhancing medical service efficiency [20][40] - As the demand for precise monitoring in medical services increases, the application of BCI in healthcare settings is expected to accelerate [20][40]

Group 1 - The A-share brain-computer interface sector experienced a rebound towards the end of trading, with Aipeng Medical rising over 4% [1] - Other stocks in the sector, including Innovation Medical, Botao Biological, Kefu Medical, and Saili Medical, also saw gains [1] - China has proposed multiple APEC cooperation projects that involve brain-computer interface technology [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The medical device bidding market is expected to maintain high prosperity in 2025, driven by policy and demand resonance, with a projected market size of CNY 193.76 billion, representing a year-on-year growth of 24% [3][11] - The upward trend for medical device companies is clear for 2026, with multiple policies expected to support the continuous development of medical innovation [4][29] - The report emphasizes the importance of high-end product localization and innovation in driving growth for leading domestic companies [33][41] Summary by Sections Bidding Review - The medical device bidding market in 2025 is projected to reach CNY 193.76 billion, with a year-on-year increase of 24%, second only to the peak in 2022 [3][11] - Monthly bidding trends show sustained high levels, with procurement amounts from July to December ranging from CNY 134 billion to CNY 285 billion [3][11] - Key segments such as medical imaging equipment and radiation therapy devices are expected to see significant growth, with year-on-year increases of 35.37% and 36.34% respectively [3][16] 2026 Outlook - The report anticipates a clear upward turning point for medical device companies in 2026, supported by policies aimed at promoting medical innovation and equipment updates [4][29] - The implementation of large-scale equipment updates and consumer replacement policies is expected to further stimulate market demand [4][29] - The report highlights the potential for domestic companies to benefit from high-end product upgrades and the commercialization of brain-computer interface technologies [4][50] Investment Recommendations - The report suggests focusing on leading domestic companies that are enhancing their high-end and intelligent medical device offerings, such as Mindray, United Imaging, and KaiLi Medical [4][33] - It also recommends monitoring companies involved in brain-computer interfaces and domestic robotics, which are expected to see significant growth in the coming years [4][50]

Core Insights - Public fund institutions have significantly increased their research activities in January, focusing on AI computing power, high-end medical technology, and new energy as the three core investment themes [1][3][5] Group 1: Research Activity - A total of 156 public fund institutions participated in A-share research in January, covering 486 stocks across 17 industries, with a total of 3,992 research instances [1] - Leading institutions such as Bosera Fund, Huaxia Fund, and Penghua Fund conducted the most research, with Bosera Fund leading at 116 instances [2] - The most researched stocks included Zhongji Xuchuang in the communications sector with 61 instances, followed by Aipeng Medical and Xiangyu Medical in the medical sector with 57 and 47 instances respectively [2] Group 2: Industry Focus - The electronics industry was the most researched, with 603 instances covering 71 stocks, followed by the machinery equipment industry with 591 instances covering 67 stocks [2][3] - Other industries such as medical biology, electric equipment, and basic chemicals also saw significant research activity, each exceeding 276 instances [3] Group 3: Emerging Trends - Brain-computer interfaces have emerged as a key focus within the high-end medical sector, driven by technological breakthroughs and commercial progress [4] - Companies like Aipeng Medical and Meihai Medical are actively engaging in brain-computer interface developments, with Aipeng Medical discussing advancements in brainwave technology [4] - The year 2026 is anticipated to be pivotal for the commercialization of invasive brain-computer interfaces, with several companies already in clinical stages [4]